THRIVE
Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines
The Big Question
What if all diseases could be cured with genetics?
The Problem
One in ten people, mostly newborns, infants, and children, suffer from chronic genetic diseases that progress rapidly, cause severe disability, reduce quality of life, and may even result in premature loss of life. Most urgent are rare diseases, affecting 30 million Americans. Despite their high unmet needs, about 95% of rare diseases have no approved treatments. Lifetime medical and other costs of rare diseases can be substantial and create financial hardship for families.
The Solution
THRIVE aims to make personalized and affordable cures available to all rare disease patients. The program intends to develop pioneering integrated platform technologies to accelerate precision genetic medicines (PGMs) and provide single-intervention precision treatments to slow, reverse, or prevent chronic diseases at the genetic level. THRIVE is designed to optimize affordability, scalability, and sustainability of lifesaving PGMs for patients through existing regional treatment centers and virtual clinics. This will allow patients to be seen and treated where they live.
Why ARPA-H
By transforming precision genetic medicines into universal, widely available cures, THRIVE exemplifies the unique health care approach needed to slow, reverse, or prevent genetic diseases for all Americans, solidifying the U.S. as the leader in realizing advanced medical treatments.
Solicitation
Notice ID: ARPA-H-SOL-25-122
ARPA-H invites interested parties to review the solicitation, which is posted and maintained on SAM.gov. The solicitation outlines the opportunity and its requirements, key dates and deadlines, submission documents and templates, evaluation criteria for submissions, and information on how to apply.
- Solution Summary Due: October 31, 2025
A summary is required to submit a full proposal. - Full Proposal Due: December 19, 2025
Encouraged submissions preferred. Additional details will be provided in a solution summary feedback letter.
Reminder: Dates are estimates and subject to change. Please reference the solicitation for the most up-to-date information.
Ready to apply? To submit a Solution Summary or Full Proposal, sign-in to the ARPA-H Solutions Portal.
Frequently Asked Questions
Review responses to common questions about this funding opportunity asked by others in the proposer community.
You can also ask a question.
Proposers' Day
This is an optional event for the proposer community to learn more about this opportunity. This event is not intended for patients, patient advocates, the media, or general interest audiences.
View the Proposers' Day recording.
Virtual Lightning Talks: October 2, 2025
For the most up-to-date information, reference the Special Notice (ARPA-H-SN-25-131) on SAM.gov.
Teaming
ARPA-H anticipates that teaming will be necessary to achieve the goals of this program. Prospective performers are encouraged to form teams with varied technical expertise to submit a research proposal.
To facilitate this process, we have created a teaming page where proposers can share their profiles and learn more about other interested parties.
Program Manager
